PACB240920C8000
- 0.07
- 0.000.00%
Pacific Biosciences of California Newsroom
Pacific Biosciences of California (PACB) Surpasses Market Returns: Some Facts Worth Knowing
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
PacBio's Stock Up on Munster Deal for Male Infertility Research
PacBio Announces the HiFi Solves Sub-fertility Consortium in Asia Pacific
Pacific Biosciences of California, Inc. (PACB): Among the Worst ARK Stocks According to Short Sellers
Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
Express News | Pacific Biosciences of California Gains in Volume Surge, Last up 6.1%
PacBio Partners With University Hospital Of Münster To Advance Male Infertility And Rare Disease Research Using Revio HiFi Long-Read Whole Genome Sequencing System For Accurate Genetic Analysis
Revio to Power Research in Male Infertility and Rare Disease at Mnster University Hospital
Revio to Power Research in Male Infertility and Rare Disease at Münster University Hospital
Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $7
Scotiabank Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $7
Scotiabank analyst Sung Ji Nam maintains $Pacific Biosciences of California(PACB.US)$ with a buy rating, and adjusts the target price from $8 to $7.According to TipRanks data, the analyst has a
Pacific Biosciences (PACB) Receives a Buy From Scotiabank
PacBio to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Institutional Owners May Be Pleased With Recent Gains After 85% Loss Over the Past Year
Applied Materials, Amcor, RLX Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Morgan Stanley Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Morgan Stanley analyst Tejas Savant maintains $Pacific Biosciences of California(PACB.US)$ with a hold rating, and maintains the target price at $2.According to TipRanks data, the analyst has a
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Piper Sandler analyst David Westenberg maintains $Pacific Biosciences of California(PACB.US)$ with a hold rating, and maintains the target price at $2.According to TipRanks data, the analyst has a
Stephens Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $2.5
Stephens analyst Mason Carrico maintains $Pacific Biosciences of California(PACB.US)$ with a buy rating, and adjusts the target price from $11 to $2.5.According to TipRanks data, the analyst has a
Piper Sandler Reaffirms Their Hold Rating on Pacific Biosciences (PACB)